Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENT-02 in mild to moderate Parkinson's disease
NCT06822517Phase 2Terminated
- Sponsor
- Ventus Therapeutics
- Start
- Mar 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing VENT-02 Dose 1 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 35 days. Started Mar 2025; status: terminated.
02
Drugs
VENT-02
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06822517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822517.